中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

894 records (took 0.026 seconds)

    LOW DOSE THERAPEUTIC TREATMENT
    5.
    发明申请
    LOW DOSE THERAPEUTIC TREATMENT 审中-公开
    低剂量治疗

    公开(公告)号：WO2017118980A1

    公开(公告)日：2017-07-13

    申请号：PCT/IL2017/050014

    申请日：2017-01-05

    Applicant: SYQE MEDICAL LTD.

    Inventor： DAVIDSON, Perry ,  KINDLER, Seth ,  ALMOG, Shlomo ,  SCHWARTZ, Binyamin ,  SCHORR, Aaron ,  ATZMONY, Daniella

    IPC: A61K31/352 ,  A61M15/00 ,  A24F47/00 ,  G06F19/00 ,  A61K9/00

    CPC classification number: G06F19/3468 ,  A61K9/008 ,  A61K31/352 ,  A61M11/042 ,  A61M15/0003 ,  A61M15/009 ,  A61M2205/52 ,  G06F19/00

    Abstract: Some embodiments of the invention relate to a system for delivering to a subject at least one pre-determined amount of THC, the system comprising: a memory which stores a scheduled regimen for delivery of THC to the subject, the scheduled regimen defining: a maximal amount of THC to be delivered, the amount being 0.75 mg THC or less, and a time period within which that amount is delivered, the time period being 2 hours or longer; a decision module which decides, according to the scheduled regimen, if a delivery should take place; and an inhaler device for delivering THC to the subject, the inhaler device comprising a controller which carries out delivery of THC based on the decision made by the decision module.

    Abstract translation: 本发明的一些实施例涉及一种用于向对象递送至少一个预定量的THC的系统，所述系统包括：存储器，其存储用于向对象递送THC的预定方案 ，预定的方案定义：最大量的待输送的THC，该量为0.75mg THC或更少，以及该量被输送的时间段，该时间段为2小时或更长时间; 根据预定方案决定是否应该进行分娩的决策模块; 以及用于向对象输送THC的吸入器装置，所述吸入器装置包括控制器，所述控制器基于决策模块做出的决定执行THC的输送。

    PHARMACEUTICAL COMPOSITION
    6.
    发明申请
    PHARMACEUTICAL COMPOSITION 审中-公开
    药物组合物

    公开(公告)号：WO2017093758A1

    公开(公告)日：2017-06-08

    申请号：PCT/GB2016/053812

    申请日：2016-12-02

    Applicant: MEXICHEM FLUOR S.A. DE C.V. ,  MEXICHEM UK LIMITED

    Inventor： CORR, Stuart ,  NOAKES, Timothy James

    IPC: A61K9/00 ,  A61K31/167 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58

    CPC classification number: A61K9/008 ,  A61K9/0073 ,  A61K9/0078 ,  A61K31/167 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58

    Abstract: A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1 - difluoroethane (R-152a).

    Abstract translation: 描述了药物组合物。 该组合物包含：（i）至少一种选自福莫特罗的福莫特罗化合物，福莫特罗的药学上可接受的盐，福莫特罗的前药，福莫特罗的溶剂合物，福莫特罗的药学上可接受的盐的溶剂合物和福莫特罗的前药的溶剂合物; （ii）至少一种皮质类固醇; （iii）包含至少一种表面活性剂化合物的表面活性剂组分; 和（iv）包含1,1-二氟乙烷（R-1​​52a）的推进剂组分。

    COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
    8.
    发明申请
    COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEXUAL DYSFUNCTION 审中-公开
    用于治疗性功能障碍的组合物和方法

    公开(公告)号：WO2016197059A1

    公开(公告)日：2016-12-08

    申请号：PCT/US2016/035910

    申请日：2016-06-03

    Applicant: RAJASEKHAR, Vijaykumar

    Inventor： RAJASEKHAR, Vijaykumar

    IPC: A61K38/22

    CPC classification number: A61K38/2257 ,  A61K9/0021 ,  A61K9/0075 ,  A61K9/008 ,  A61K47/60

    Abstract: Described herein are pharmaceutical compositions for the treatment of sexual dysfunction in an individual In some embodiments, the pharmaceutical composition includes a prolactin variant having a glycine residue at position 129 substituted with an amino acid other than glycine. In one embodiment, the amino acid is arginine. In one embodiment, the prolactin variant further comprises an N-terminal deletion. In one embodiment, the prolactin variant is conjugated to a H(OCH 2 CH 2 ) n OH molecule (e.g., a equals any number from 1 to 6). In some embodiments, the pharmaceutical composition is delivered to the individual by a. microneedle patch or an inhalable formulation.

    Abstract translation: 本文描述的是用于治疗个体性功能障碍的药物组合物。在一些实施方案中，药物组合物包含在129位被甘氨酸残基取代的不同于甘氨酸的氨基酸的催乳素变体。 在一个实施方案中，氨基酸是精氨酸。 在一个实施方案中，催乳素变体还包含N-末端缺失。 在一个实施方案中，催乳素变体与H（OCH 2 CH 2）n OH分子缀合（例如，等于1至6的任何数）。 在一些实施方案中，药物组合物通过a。 微针贴片或可吸入制剂。

    PHARMACEUTICAL COMPOSITIONS COMPRISING ARFORMOTEROL AND GLYCOPYRRONIUM
    9.
    发明申请
    PHARMACEUTICAL COMPOSITIONS COMPRISING ARFORMOTEROL AND GLYCOPYRRONIUM 审中-公开
    包含阿莫斯醇和甘氨酸的药物组合物

    公开(公告)号：WO2016170518A1

    公开(公告)日：2016-10-27

    申请号：PCT/IB2016/052328

    申请日：2016-04-25

    Applicant: GLENMARK SPECIALTY S.A.

    Inventor： DHUPPAD, Ulhas ,  KOPPENHAGEN, Franciscus ,  KATKURWAR, Ashok ,  CHANAGARE, Ramakant ,  SHIROLE, Kautik ,  PATIL, Jitendra ,  ANKAM, Rajesh ,  PATEL, Nainesh

    IPC: A61K9/00 ,  A61K9/14 ,  A61K31/00

    CPC classification number: A61K9/008 ,  A61K31/167 ,  A61K31/40 ,  A61K47/06 ,  A61K47/10 ,  A61K47/32 ,  A61K2300/00

    Abstract: Described herein is a fixed dose pharmaceutical composition containing arformoterol or its salt and a glycopyrronium salt. Particularly, a fixed dose pharmaceutical composition in the form of an aerosol or an aerosolizable for inhalation administration includes arformoterol or its salt, a glycopyrronium salt and pharmaceutically acceptable excipients. Also described is a process for preparing the compositions and its use for the treatment of asthma and/or chronic obstructive pulmonary disease in a subject in need thereof. Also described are pharmaceutical compositions that include an effective amount of arformoterol (or its salt), a glycopyrronium salt or its combination in the form of a suspension or solution, and methods of their preparation.

    Abstract translation: 本文描述的是含有阿霉素或其盐和格隆铵盐的固定剂量药物组合物。 特别地，以气溶胶形式或可雾化形式用于吸入给药的固定剂量药物组合物包括阿莫曲坦或其盐，格隆铵盐和药学上可接受的赋形剂。 还描述了一种制备组合物的方法及其在有需要的受试者中治疗哮喘和/或慢性阻塞性肺疾病的用途。 还描述了包含有效量的阿霉素（或其盐），格隆铵盐或其悬浮液或溶液形式的组合的药物组合物及其制备方法。

Patent Agency Ranking